Lead Product(s) : H5N8 A/Astrakhan Virus Vaccine,Squalene API
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : BARDA
Deal Size : $30.1 million
Deal Type : Agreement
Details : Under the terms of the agreement, CSL Seqirus will deliver an H5N8 A/Astrakhan virus vaccine candidate and will then sponsor a subsequent Phase 2 clinical trial to evaluate the candidate along with CSL Seqirus' proprietary adjuvant MF59®.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 10, 2022
Lead Product(s) : H5N8 A/Astrakhan Virus Vaccine,Squalene API
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : BARDA
Deal Size : $30.1 million
Deal Type : Agreement
Reset All
